Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2025-04-24 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
2024年度独立董事述职报告（谢晓燕）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2024 by an independent director of the company. It details the director's attendance at board and shareholder meetings, committee work, communication with auditors, and overall evaluation of their duties. The content focuses on governance, director responsibilities, and oversight activities rather than financial results or audit opinions. It does not contain financial statements or earnings data, nor is it an announcement of a report publication. The document fits the category of Board/Management Information (MANG) as it relates to the activities and reports of a board member rather than a full annual report, audit report, or other financial filings.
2025-04-24 Chinese
第四届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the fourth meeting of the fourth board of directors of Inner Mongolia Datang Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to various reports and announcements published separately on the Beijing Stock Exchange information platform. The document itself does not contain the full reports but rather summarizes and approves them, indicating that these reports are disclosed elsewhere. This type of document is a formal announcement of board meeting resolutions, which fits the category of Board/Management Information (MANG). It is not the full annual report, audit report, or other detailed filings, but a board meeting resolution announcement.
2025-04-24 Chinese
2024年度独立董事述职报告（张剑）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告（张剑）" which translates to "2024 Annual Independent Director's Work Report (Zhang Jian)". It details the independent director's duties, attendance at board and shareholder meetings, committee work, communication with auditors, and overall evaluation of their role during the year 2024. The content focuses on the director's report on their activities and responsibilities rather than financial results or audit opinions. It is a management-related report about the director's work and governance role, not an audit report or annual financial report. This fits best under Board/Management Information (MANG) as it relates to board member activities and governance reporting. The document length is 2563 characters, which is sufficient for a detailed report but not a full annual report or audit report. Therefore, the classification is MANG with high confidence.
2025-04-24 Chinese
股票解除限售公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the lifting of stock trading restrictions (解除限售公告) for certain shares held by former directors and supervisors. It details the number of shares becoming tradable, the shareholders involved, and the updated share capital structure. There is no financial data, earnings information, or management discussion. The document is a regulatory announcement about share status changes, specifically about lifting trading restrictions on shares. It does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. It is best classified as a Regulatory Filing (RNS) because it is a formal disclosure related to share trading status but does not match more specific categories such as Share Issue/Capital Change or Transaction in Own Shares, as it concerns lifting restrictions rather than new issuance or buybacks. The document length is short (1567 characters), and it is a direct announcement, not a report publication notice.
2025-03-13 Chinese
2024年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2024 年年度业绩快报公告" which translates to "2024 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2024, including revenue, profit, and other key financial metrics. The text explicitly states that the data is preliminary, unaudited, and subject to the final audited annual report. It also includes a risk warning advising investors to be cautious and that the final data will be in the formal annual report. The document length is 1763 characters, which is relatively short and consistent with a brief earnings or performance update rather than a full annual report. The document does not contain full financial statements or detailed analysis but rather a summary of key financial data and performance highlights. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not the full Annual Report (10-K), nor is it a report publication announcement (RPA) because it contains substantive financial data, not just a notice of report availability. Therefore, the correct classification is Earnings Release (ER). FY 2024
2025-02-26 Chinese
高级管理人员任命公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the appointment of a senior management personnel, specifically the appointment of Mr. Wu Bo as the company's financial officer. It details the nomination, approval votes, qualifications, and the impact of the appointment on the company. There is no financial data, earnings information, or report publication mentioned. The content focuses on management changes and complies with relevant laws and company rules. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or regulatory filing. Hence, the classification is MANG with high confidence.
2024-10-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.